1832 Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

1832 Asset Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-234,000	Closed	-$1.85M	–	753
2016 Q1	$1.85M	Hold	234,000	–	–	﹤0.01%	391
2015 Q4	$1.16M	Hold	234,000	–	–	0.01%	391
2015 Q3	$827K	Sell	234,000 -133,000	-36%	-$891K	﹤0.01%	404
2015 Q2	$3.66M	Sell	367,000 -36,800	-9%	-$395K	0.01%	363
2015 Q1	$5.15M	Buy	403,800 +92,300	+30%	+$1.19M	0.02%	287
2014 Q4	$4.4M	Buy	+311,500	New	+$4.83M	0.01%	350

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

1832 Asset Management's KERX Position: Q2 2016 in Review

1832 Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2016, closing a stake of 234,000 shares — an estimated $1.85M sold.

1832 Asset Management first reported a position in KERX in Q4 2014 and held it in 6 quarters. The position peaked at $5.15M in Q1 2015. 118 funds tracked by Wall St. Rank hold KERX as of Q2 2016.

1832 Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
1832 Asset Management sold 234,000 Keryx Biopharmaceuticals Inc shares in Q2 2016, an estimated $1.85M.
1832 Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2014 and held it in 6 quarters.
1832 Asset Management's Keryx Biopharmaceuticals Inc position peaked at $5.15M in Q1 2015.
118 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2016.

Based on 1832 Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.